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ABSTRACT 
We investigate mutations and correlates according to HIV-1 subtype after virological failure of 
standard first-line antiretroviral therapy (ART) (non-nucleoside/nucleotide reverse transcriptase 
inhibitor (NNRTI) + 2 nucleoside/nucleotide reverse transcriptase inhibitor (N(t)RTI). 
SECOND-LINE study participants were assessed at baseline for HIV-1 subtype, demographics, HIV-1 
history, ART exposure, viral load (VL), CD4+ count and genotypic ART resistance. We used backwards 
stepwise multivariate regression (MVA) to assess associations between baseline variables and 
presence of ≥3N(t)RTI mutations, ≥1NNRTI mutation, ≥3thymidine-analogue N(t)RTI (ta-N(t)RTI) 
mutations (TAMs), the K65/K70 mutation, and predicted etravirine(ETV)/rilpivirine(RPV) activity.  
Of 541 participants, 491(91%) had successfully characterised baseline viral isolates.  Subtype 
distribution: B (n=123, 25%), C (n=202, 41%), CRF01_AE (n=109, 22%), G (n=25, 5%) and CRF02_AG 
(n=27, 5%). Baseline CD4+ 200-394 cells/mm3 was associated with <3N(t)RTI mutations 
(OR=0.47;95%CI 0.29-0.77;p=0.003), absence of the K65/K70 mutation (OR=0.43;95%CI 0.26-
0.73;p=0.002) and higher ETV sensitivity (OR=0.52;95%CI 0.35-0.78;p=0.002). Recent Tenofovir 
(TDF)-use was associated with K65/K70 mutations (OR=8.91;95%CI 5.00-15.85;p<0.001). Subtype 
CRF01_AE was associated with ≥3N(t)RTI mutations (OR=2.34;95%CI 1.31-4.17;p=0.004) and higher 
RPV resistance (OR=2.13;95%CI 1.30-3.49;p=0.003), and subtype C with <3TAMs (OR=0.45;95%CI 
0.21-0.99;p=0.015). Subtypes CRF01_AE (OR=2.46; 95%CI1.26-4.78;p=0.008) and G (OR=4.77;95%CI 
1.44-15.76;p=0.01) were associated with K65/K70 mutations. Higher VL at confirmed first-line 
virological failure was associated with ≥3N(t)RTI mutations (OR=1.39; 95%CI 1.07-1.78; p=0.013) and 
≥3TAMs (OR=1.62;95%CI 1.15-2.29;p=0.006).   
The associations of first-line resistance mutations across the HIV-1 subtypes in this study are 
consistent with knowledge derived from subtype B, with some exceptions. Patterns of resistance 
after failure of a first-line ta-N(t)RTI regimen support using TDF in N(t)RTI-containing second-line 
regimens, or using N(t)RTI-sparing regimens.   
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INTRODUCTION/BACKGROUND 
It is estimated that since 1995, combination antiretroviral therapy (cART) has saved 14 million life 
years in low- and middle-income countries (LMIC), including 9 million in sub-Saharan Africa1.  
WHO guidelines recommend two nucleos(t)ide reverse transcriptase inhibitors (N(t)RTI) plus either a 
non-nucleoside reverse transcriptase inhibitor (NNRTI) or a boosted protease inhibitor (PI) for first 
and second line regimens respectively2. In LMICs it is common practice for HIV-positive individuals to 
receive zidovudine (AZT), stavudine (d4T) or tenofovir disoproxil fumerate (TDF) as the first N(t)RTI 
component combined with lamivudine (3TC) as the second N(t)RTI component of the 2N(t)RTI 
backbone, combined with an NNRTI, usually nevirapine (NVP) or efavirenz (EFV)3. The WHO-
preferred component since the most recent iteration of the WHO antiretroviral therapy (ART) 
Guidelines for first line regimen  is EFV+TDF/3TC2 although for various reasons the transition to the 
exclusive use of this WHO recommended regimen has not been universal. 
Despite the great successes in supporting access to HIV-1 care in LMIC over the past decade, HIV-1 
remains a pressing global health problem. The massive scale-up of cART following the WHO ‘3 by 5’ 
initiative, has come at the inevitable cost of some degree of HIV drug resistance (HIVDR)4. Significant 
population-level HIVDR could limit future therapy options requiring new and expensive treatment 
regimens5. WHO has developed a global HIVDR prevention strategy that includes acquired resistance 
surveillance and viral load (VL) monitoring. This is challenging due to costs and the availability of the 
requisite technologies, and results have been mixed4,6,7. 
Drug resistance data has historically been relatively limited to subtype B, the predominant subtype 
in resource-rich countries which accounts for only about 10% of global infections. The differences in 
HIVDR amongst other HIV-1 subtypes is far less well researched and only partially understood8–11. 
Earlier studies have suggested minimal differences in resistance patterns between subtypes. In 
regard to N(t)RTI resistance mutations, a study from Zimbabwe in 2002 found that subtypes B and C 
selected mostly the same mutations under similar drug pressure12. However, more recently, it has 
been suggested that subtype C may have a higher propensity for selection of resistance through the 
K65R mutation13,14. Regarding NNRTI resistance mutations, the V106M mutation is commonly seen 
in subtypes C and CRF01_AE after therapy with efavirenz or nevirapine, whereas in subtype B 
infections  V106A more commonly emerges15–18. Under PI drug pressure, non-subtype B viruses 
commonly select particular mutations compared to subtype B viruses, due to polymorphisms in the 
PI coding regions associated with each subtype. Subtypes A, C and CRF01_AE often select for M89T 
due to a M89 polymorphism, leading to substantial resistance to nelfinavir, atazanavir and 
lopinavir19,20. There are few studies comparing HIVDR profiles between subtypes in diverse, well-
characterized cohorts. One such instance is Huang et al.’s analysis of a multi-cohort, multi-subtype 
dataset21, building upon earlier work by Kantor et al22. The latter study found little difference in 
resistance mutation positions between non-B and subtype B viruses. The former found lower 
mutation frequencies in subtype B and higher frequencies in subtypes C and CRF01_AE. 
This study aims to describe patterns of drug resistance mutations and their correlates following 
virological failure (VF) of first-line therapy consisting of NNRTI+2N(t)RTIs in patients enrolled in the 
SECOND-LINE study23. 
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MATERIALS AND METHODS 
Study Design and Participants 
A full description of the SECOND-LINE trial has been published23. In brief, SECOND-LINE compared 
the use of ritonavir boosted-lopinavir combined with either 2-3N(t)RTIs or with raltegravir alone for 
second-line treatment after first-line VF.  SECOND-LINE was a randomised, parallel, open-label, 
multicentre, international trial, enrolling patients from 37 sites in 14 hig—and middle-income 
coutries 23. This sub-study was approved by the UNSW Australia Human Research Ethics Committee 
as well as all relevant local institutions23. 
HIVDR Testing 
In order to qualify for SECOND-LINE study enrolment prospective participants had to have a 
confirmed viral load ≥500 copies/mL drawn at least 7 days apart.. All enrolled participants were 
advised to continue to take their failing regimen until they received their randomised second-line 
regimen on the day of the baseline visit.  
Patients were assessed at week 0 (baseline) for demographics, HIV-1 infection history and previous 
cART exposure using an electronic case report form. Patients were asked to estimate the month and 
year of infection; if unknown, then the date of first positive HIV-1 test was used. Blood samples were 
collected for plasma VL measurement, genotypic resistance testing, and T-cell counts. VL Viral load 
and genotypic resistance testing for study analysis purposes was performed using samples stored at 
a single central laboratory (HIV Immunovirology Laboratory, St Vincent’s Hospital Centre for Applied 
Medical Research, Sydney, Australia).  The reverse transcriptase and protease regions were 
sequenced using the ViroSeq HIV-1 genotyping system v2.0 (catalogue no. 4J94-93; distribution:  
Abbott Molecular; manufacturer: Celera Corporation, Alameda, CA 94502 USA). The integrase region 
was sequenced using the ViroSeq HIV-1 integrase genotyping kit v1.0 RUO (catalogue no. 04J94-71; 
distribution: Abbott Molecular; manufacturer: Celera Corporation, Alameda, CA 94502 USA). Major 
resistance mutations and subtypes were identified according to the Stanford database version 
6.3.124. Major mutations are defined by the Stanford database as those that make major 
contributions to reducing drug susceptibility, usually with a penalty score of 30 to 60. Rilpivirine 
(RPV) resistance was calculated according to the Stanford HIVdb algorithm, where RPV resistance 
mutations are assigned drug penalty scores which are added to infer 1 of 5 resistance levels: 
susceptible, potential low, low, intermediate, and high24. Etravirine (ETV) sensitivity was evaluated 
using a published weighted scoring algorithm based on 17 ETV resistance-associated mutations. 
Scores are added and stratified into highest, intermediate and reduced virological response25,26. 
Statistical Analysis 
Baseline characteristics and ARV drug resistance profiles were described according to subtype. We 
analysed for the following outcomes at baseline: <3 or ≥3 major N(t)RTI mutations, zero or ≥1 major 
NNRTI mutations, <3 or ≥3 thymidine analogue mutations (TAMs), the K65 or K70 mutations; 
sensitivity to ETV and sensitivity to RPV. For each category we assessed for association with HIV-1 
subtype, age, gender, CD4+ T cells/mm3 (CD4), VL, most recent N(t)RTI and NNRTI, treatment time 
on thymidine analogues-N(t)RTIs (ta-N(t)RTIs), and exposure to TDF, NVP and EFV. Variables with 
association at p-value <0.2 were included in multivariate analysis models. Previous exposure to TDF, 
NVP and EFV were dropped from the multivariate analyses due to being significantly correlated with 
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the most recent N(t)RTI and NNRTI (r=0.7668, r=0.8705, r=-0.8437 respectively). Multivariate models 
were built using binary logistic and ordinal logistic regression methods with backward stepwise 
elimination (inclusion p<0.05). Results with p<0.05 were considered statistically significant. All 
analyses were done using Stata 12 software. Outcomes were assessed in study participants who had 
an amplified sequence at baseline. We made no imputations for missing data. Overall, we 
hypothesized that rates, types and predictors of mutations in non-B subtypes would be similar to 
experience in the western world with subtype B viruses.
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RESULTS 
Of the 541 participants in the SECOND-LINE study, 491 (91%) had a successfully amplified genotypic 
antiretroviral resistance test (GART) for analysis (Figure 1)23. The mean age (SD) of the group was 
38.6 (8.9) years. Participants were 56% male, 42% were Asian, 37% African, 14% Hispanic, and 8% 
Caucasian. The mean estimated duration of infection (SD) was 6.6 (4.1) years, and treatment 
duration 4.1 (2.9) years. At baseline 51% had a CD4 cell count of <200 cells/mm3, 33% 200-349 
cells/mm3, 12% 350-499 cells/mm3 and 4% ≥500 cells/mm3. . The mean VL (SD) was 4.3 (0.9) log10 
copies/mL; 80% had a viral load ≤100,000 copies/mL. The majority were receiving ta-N(t)RTIs (77%) 
at the time of screening, whilst the NNRTI component was split 50/50 for EFV and NVP. Eight nine 
percent (89%)  had been exposed to  ta-N(t)RTIs in previously, 21% to TDF, 57% to EFV, and 57% to 
NVP (Table 1). 
The most prevalent subtype was subtype C (41%), followed by B (25%), CRF01_AE (22%), CRF02_AG 
(5%) and G (5%). Those participants with subtype B were54% Hispanics and 32% Caucasians; those 
with subtype C were 61% African and 39% Asian. Subtype CRF01_AE was almost exclusively seen in 
Asian participants (98%). Subtypes G and CRF02_AG were exclusively seen in African participants. 
Two patients carried subtype F, and 1 each carried subtypes A, D and K. Of 491 patients, 452 (92%) 
had at least 1 major N(t)RTI mutation and four hundred and seventy-six (97%) of patients had at 
least one major NNRTI mutation. The most common N(t)RTI mutation was at M184 (86%) followed 
by TAMs at codons 215 (28%), 67 (23%), 70 (20%), 219 (18%) and 41 (17%). The most common 
NNRTI mutation was K103 (52%) followed by Y181 (28%) (Table 1, Figure 2). 
Two hundred and ninety (59%) patients had <3 major N(t)RTI mutations. Having ≥3 major N(t)RTI 
mutations was significantly associated with being infected with subtype CRF01_AE (OR=2.34, 
CI95%=1.31-4.17, p=0.004), a higher SECOND-LINE study baseline VL (OR=1.39, CI95%=1.07-1.78, 
p=0.006), having received TDF as the most recent N(t)RTI (OR=3.87, CI95%=1.97-7.59, p<0.001), 
having a drug other than TDF or a ta-N(t)RTI as the most recent N(t)RTI (OR=8.35, CI95%=1.97-35.45, 
p=0.004), and a longer total time receiving ta-N(t)RTIs (all quartiles significant compared to 1st 
quartile, p<0.001, see Table 2a). Those with CD4+ cell counts between 200-349 cells/mm3 compared 
to <200 cells/mm3 at SECOND-LINE study baseline were more likely to have <3 mutations (OR=0.47, 
CI95%=0.29-0.77, p=0.003) (Table 2a).  
Four hundred and thirty (88%) patients had <3 TAMs. Having <3 TAMs was significantly associated 
with subtype C (OR=0.45, CI95%=0.21-0.99, p=0.047). Having ≥3 TAMs was significantly associated 
with higher viral load at the time of confirmed first-line VF (OR=1.62, CI95%=1.15-2.29, p=0.006), 
and longer total time receiving ta-N(t)RTIs (p<0.001, see Table 2c). 
One hundred and fifty-two (31%) patients had a major N(t)RTI mutation at either K65 or K70. Having 
either a K65 or K70 mutation was associated with subtypes CRF01_AE (OR=2.46, CI95%=1.26-4.78, 
p=0.008) and G (OR=4.77, CI95%=1.44-15.76, p=0.010), and having TDF as part of a recent cART 
regimen (OR=8.91, CI95%=5.00-15.85, p<0.001). Being female (OR=0.62, CI95%=0.38-1.00, p=0.049), 
and having a CD4+ cell count between 200-349 cells/mm3 compared to <200 cells/mm3 (OR=0.43, 
CI95%=0.26-0.73, p=0.002) was significantly associated with not having either mutation (Table 2d). 
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Two hundred and ninety-one (59%) viruses were classified as being highly responsive to ETV, 156 
(32%) as intermediate and 44 (9%) as reduced. Older age (OR=0.98, CI95%=0.96-1.00, p=0.046) and 
having a CD4+ cell count >200 cells/mm3 (see Table 2e) were associated with better ETV responses, 
whilst receiving NVP as the most recent NNRTI was associated with a reduced response compared to 
those receiving EFV (OR=2.75, CI95%=1.89-4.00 p<0.001) (Table 2e). 
Two hundred and seventy-six (56%) viruses displayed resistance to RPV (low-, intermediate or high-
level resistance); 180 (37%) were fully susceptible. Higher degrees of resistance to RPV were 
associated with subtype CRF01_AE viruses (OR=2.13, CI95%=1.30-3.49, p=0.003), having received 
NVP compared to EFV as the most recent NNRTI (OR=1.72, CI95%=1.22-2.43, p=0.002), and being 
female (OR=1.47, CI95%=1.04-2.09, p=0.031) (Table 2f). 
Patients who were older were less likely to have a major NNRTI mutation (OR=0.94, CI95%=0.89-
0.99, p=0.015) (Table 2b).  
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DISCUSSION 
This study describes the distribution and patterns of HIVDR mutations in a cohort of 491 HIV-1 
positive individuals who had failed first-line cART and whose plasma samples underwent successful 
antiretroviral drug resistance genotyping. Multivariate analysis demonstrated associations with 
selected mutations that are on the whole consistent with prior research findings reported from 
studies of HIV-1 B subtype viruses. In general, the longer a patient received first-line NNRTI+2N(t)RTI  
the more likely they were to select resistance mutations; those displaying a K65 or K70 mutation 
were more likely to have recently received a TDF-containing first-line ART regimen; participants with 
CD4+ cell counts >200 cells/mm3 at first-line VF were less likely to have mutations and more likely to 
have a better predicted response to ETV than those with lower CD4+ counts at VF. 
However, there were a number of findings that were not consistent with current understandings of 
resistance and its correlates and consequences. Study plasma viral load at the time of first-line cART 
VF was found to be an important predictor for both the number of N(t)RTI mutations and number of 
TAMs acquired. Wallis et al. found that the degree of N(t)RTI and NNRTI resistance after first-line 
failure was associated with higher VL at VF (>1000 copies/mL) in a non-subtype B cohort (66% C, 18% 
CRF01_AE)3. Fofana et al. found that high VL at failure is associated with resistance to abacavir and 
TDF27. Hassan et al. also found high VL (>4 log10 copies/mL) to be associated with higher prevalence 
of HIVDR in a cohort of first-line VF (>400 copies/mL) patients28.. This finding is interesting given it is 
generally believed that the more mutated the virus, the less replication competent it becomes. If 
this were true then one might expect to see an association between highly mutated viruses and 
lower viral loads compared with less mutated viruses or wild type virus. Our finding however should 
be interpreted with caution. While participnats were instructed to continue to take their failing first-
line ART until the baseline study visit this was not monitored and we therefore cannot guarantee 
that it occurred. If many participants stopped their first-line ART prior to the baseline visit then it is 
possible that the finding merely reflects viral replication in the absence of ART drug pressure. It may 
also be the case that these participants selected resistance associated mutations as a direct 
consequence of poor adherence while receiving their first-line ART, making assumptions about 
adherence to the failing therapy hazardous (reference the Lancet HIV SECOND-LINE analysis from 
Jan 2015 here [29]). 
However, the presence of resistance mutations at first-line cART failure does not necessarily result in 
poorer performance of second-line cART, as seen in an exploratory analysis of the SECOND-LINE 
dataset29. In that study, patients with high degrees of N(t)RTI resistance at baseline did as well as 
those with little to no resistance, suggesting factors like adherence are more important than degree 
of baseline N(t)RTI resistance in a successful virological response to second-line ART29. Furthermore, 
a recent presentation on the impact of N(t)RTI resistance on second-line therapy performance in the 
EARNEST study showed clear benefit in PI/N(t)RTI second-line therapy despite little or no predicted 
N(t)RTI activity in resistance testing30. These results suggest that an earlier switch from a failing first-
line regimen and investment in adherence-improving strategies may be favourable over GART 
implementation in LMIC per se which is expensive, complex and difficult to sustain. Simple 
measurement of the presence/absence of the presence or absence of antiretroviral drug in an 
untimed blood plasma sample at a routine monitoring visit may be a useful and less technologically 
complicated intervention to monitor adherence and intervene before resistance is selected31. Recent 
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research has provided evidence that mobile phone message reminders are highly effective in 
improving cART adherence and VL suppression in LMIC32,33. 
Being younger was significantly associated with having major NNRTI mutations and worse ETV 
sensitivity. This result most likely reflects the better ART adherence generally displayed by older 
people living with HIV-1 and receiving ART.  It has been repeatedly shown that older patients are 
more adherent to cART34 and that specifically for NNRTIs, mutations are uncommon in highly 
adherent patients35. Hassan et al. found in a rural Kenyan cohort that younger age was a potent risk 
factor for VF and HIVDR development28.  
Our results also suggest that the propensity for HIVDR mutations of the various HIV-1 subtypes may 
not always be consistent with knowledge derived from subtype B. Subtype CRF01_AE was 
significantly associated with having ≥3 major N(t)RTI mutations compared to subtype B. This is a 
concern for South East Asian LMIC where the CRF01_AE subtype is dominant and there is expanding 
cART use11. Other factors, for which data was unavailable, may have contributed to this result, such 
as adherence, drug availability, and frequency and type of monitoring available to these patients. 
Subtype C was less likely to be associated with having ≥3 TAMs compared to subtype B. This finding 
is consistent with the hypothesis that subtype B may be more likely to generate TAMs due to 
frequent pausing at codon 67, leading to D67N mutations and TAMs36,37 There is broad evidence 
suggesting that subtype C has a higher propensity to select for the K65R mutation13,14,36,37. However, 
our results suggest that subtypes CRF01_AE and G may have a greater propensity to select either 
K65 or K70 mutations.  
The strongest predictor of a K65 or K70 mutation was whether a participant took TDF as part of their 
most recent cART regimen prior to screening. This is consistent with our knowledge of the 
association between TDF-use and selection of these signature mutations38. The 2013 WHO 
guidelines recommend the use of ta-N(t)RTIs plus 3TC as the preferred N(t)RTI-containing second-
line cART regimen2. Our results support this recommednation given the associations we found for 3 
non-B subtypes to have greater propensity for selection of TDF-associated mutations. However, with 
d4T having fallen out of favour as a result of its toxicity, AZT is the preferred ta-N(t)RTI. Anaemia and 
other well described AZT-associated adverse effects (headache, gastrointestinal disturbance, 
lipoatrophy) may well become problematic as use of AZT increases in people switching to second-
line cART. A recent study examining the possibility of AZT dose reduction from a 600mg bid to 
400mg total daily dose  was not promising in this regard.39. The SECOND-LINE study has shown that 
ritonavir-boosted lopinavir plus raltegravir is a reasonable, efficacious and safe alternative to 
recycling N(t)RTIs in second-line cART23,40 and this result has been confirmed by both the EARNEST 
and ACTG 5237 studies (Add theseto the refrences; the ACTG study has just been electronically 
published in Lancet – check authors Alberto de la Rosa (first) and Ann Collier (last) in Pub Med) 
Those receiving a NVP-containing regimen prior to screening had a poorer predicted response to ETV 
and higher resistance to RPV compared to those on EFV-containing regimens. NVP selects for both 
Y181C and G190A, affecting susceptibility to both ETV and RPV41 whilst the K103 mutation 
associated with EFV use does not. Some studies have shown a relationship between receiving NVP in 
failing regimens leading to selection of resistance mutations compromising the efficacy of ETV. In 
both a Thai cohort of mostly CRF01_AE subtypes and a Nigerian cohort of various non-B subtypes, 
there was an association between failing NVP-containing regimens and sub-optimal predicted ETV 
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activity42,43. A study of a similar cohort of virologically-failing (not virologically monitored) people 
with HIV in South Africa in which 89% were taking EFV found that only 9% had selected for ETV 
resistance41. Given this, EFV may be the more appropriate first-line NNRTI choice in settings in which 
there is not the capacity to detect early VF by resistance testing. Further research into the rate of 
EFV resistance mutation development may help guide timing of VL tests in LMIC to help patients get 
therapeutic value from ETV in 3rd line ART (the WHO recommendation is for bDRV+RAL+ETV ± 
N(t)RTIs). 
Our study has limitations. It is a cross–sectional study and therefore inferences about causality on 
the basis of associations should only be made with caution. In some cases the possibility of reverse 
causality should be considered. Our results may be affected by data that was not collected, such as 
baseline patient demographic status participant adherence to their first-line cART or how long they 
had been failing treatment prior to enrolment in SECOND-LINE. Statistically, there are weaknesses 
with regard to some small cell sizes, increasing the likelihood of making Type II errors. Furthermore, 
we performed a relatively large number of statistical tests increasing the probability of finding 
spurious associations. We did not adjust P-values for multiple comparisons. Nevertheless, this study 
has its strengths. Its population is large and broad, having been performed within an RCT recruited 
across multiple centres in 15 countries. A range of subtypes are represented providing a good basis 
for comparisons between subtypes. 
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CONCLUSION 
Our study has generally given results consistent with our knowledge of HIV-1 resistance 
characteristics made on the basis of studies of subtype B. Higher viral load at identification of VF and 
more time spent on treatment increases the likelihood of having mutations, whilst those with higher 
CD4 cell counts at identification of VF were less likely to have mutations. However, there are some 
novel and interesting differences between subtypes. Subtype CRF01_AE was associated with more 
N(t)RTI and RPV resistance, and subtype C with less ta-N(t)RTI resistance. Subtypes CRF01_AE and G 
were more likely to select for K65 or K70 mutations. WHO currently recommends TDF-based 
regimens for all first-line regimens (EFV+TDF+3[F]TC single tablet preferred). Therefore, in light of 
these results ta-N(t)RTI + 3TC as the second-line 2N(t)RTI backbone seems an appropriate choice as 
this backbone combination would most likely retain antiretroviral activity. The nucleoside-sparing 
boosted-PI plus raltegravir regimen is also an efficacious and safe second-line ART alternative and 
would avoid the adverse effects of ta-N(t)RTIs. The results also support current recommdations to 
commence ART at higher CD4 T-cell counts if possible. Further research is needed in the 
development of cheap and reliable point-of-care testing,  determine optimal testing frequency and 
deployment and to clearly determine if virological testing is genuinely required in orde to optimise 
the prescription and use of ART worldwide. 
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